Welcome to our dedicated page for Revium Recovery SEC filings (Ticker: RVRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revium Rx filings document the company’s biopharmaceutical business, securities registration activity, governance changes, and public-company status. The filing record includes amended Form S-1 registration statements for a Securities Act offering, identifying the company as a Nevada issuer classified as a smaller reporting company and emerging growth company.
RVRC disclosures also cover material events such as executive appointments, capital-structure and offering matters, and formal updates tied to its development-stage therapeutic platform. The filings provide regulatory context for the company’s transition from Revium Recovery Inc. to Revium Rx and its focus on lipid-based nano and micro particle medicines through LipoVation Ltd.
Revium Rx. reported a leadership change in its finance function. On May 27, 2026, Chief Financial Officer Arie Gordashnikov resigned from the company and its subsidiaries, effective immediately. The company states that his resignation did not result from any disagreement regarding operations, policies, or practices.
On the same date, the Board appointed Igor Bluvstein as the new Chief Financial Officer of Revium Rx. and its subsidiaries, also effective immediately. Bluvstein brings more than 17 years of financial leadership experience across pharmaceutical, digital health, biotechnology, e-commerce, and petrochemical industries and is a Certified Public Accountant. In connection with his appointment, he will receive a monthly retainer of NIS17,000 plus VAT.
Revium Rx reported a net loss of $725,000 for the quarter ended March 31, 2026, similar to the prior year, as it continues to generate no revenue while funding pre-clinical drug development.
Research and development expenses rose to $473,000, reflecting progress on its Nano-Mupirocin program, while general and administrative costs fell to $266,000 due mainly to lower share-based compensation. Cash, cash equivalents and short-term deposits totaled about $2.1 million, with operating activities using $541,000 of cash in the quarter.
The company reported an accumulated deficit of $25.7 million and explicitly stated that these conditions raise substantial doubt about its ability to continue as a going concern. Management plans to seek additional financing but has no binding commitments. Operations are also exposed to regional geopolitical risks in Israel, and management concluded disclosure controls and procedures are not effective.
Revium Rx named Amir Avraham as permanent Chief Executive Officer, effective February 1, 2026, after serving in the role on an interim basis. His compensation includes a monthly salary of NIS 55,000, eligibility for an annual discretionary cash bonus, and a one-time $50,000 bonus tied to raising at least $5 million in new equity investments within 18 months.
Under the company’s Global Share Incentive Plan, he is to receive options for 1,300,000 common shares starting vesting on February 1, 2026, plus additional option grants of 300,000 shares each upon meeting $3,000,000 investment and M&A milestones. The company also appointed Shlomi Schwartzblat as a director and Chairman of the Board, with his term running until the 2026 annual stockholder meeting.
Revium Rx files its annual report describing a shift into pre‑clinical nanoparticle‑based biopharmaceuticals, centered on infectious diseases, oncology and vaccines. The company reported an aggregate market value of common equity held by non‑affiliates of about $14.3 million as of June 30, 2025 and had 61,321,100 common shares outstanding as of March 30, 2026.
Its lead asset, Nano‑Mupirocin, is a liposomal formulation of the antibiotic mupirocin being developed for severe antimicrobial‑resistant infections, supported by multiple animal studies and composition‑of‑matter patents lasting to 2035. A second candidate, Nano‑Candesartan, targets solid tumors such as pancreatic cancer as part of combination therapy, while a separate Liposomal Protein‑Loaded Technology platform is being explored for vaccines against viruses like COVID‑19 and West Nile. All programs remain pre‑clinical and will require substantial additional funding, partnerships and regulatory success.
Revium Rx filed Amendment No. 5 to its Form S-1 registration statement as an exhibits-only update. The company states that this amendment consists of the facing page, an explanatory note, the signature page, the exhibits index, and the filed exhibits, while the remainder of the registration statement is unchanged and therefore omitted. The filing also restates that the registrant may delay the registration statement’s effective date through further amendments and includes signatures from senior executives and directors, along with a power of attorney appointing an attorney-in-fact to sign future amendments.
Revium Rx is registering up to 1,562,500 units in a self-underwritten primary offering and up to 37,625,790 shares of common stock for resale by existing stockholders. Each unit is priced at $3.20 and includes two shares of common stock and one warrant exercisable at $2.40 for three years, creating up to 1,562,500 additional shares upon warrant exercise. The company expects about $4.4 million in net proceeds if all units are sold and plans to allocate roughly 70%–80% to developing its lipid-based drug candidates and clinical trials, and 20%–30% to exploring additional indications. Revium Rx had 60,729,100 shares outstanding before the offering. The resale shareholders may sell their 37,625,790 shares at $1.00 per share until an uplisting or national exchange listing, which the company warns could pressure its stock price and make the primary offering less attractive. As a preclinical biotech with a history of losses, the company highlights significant funding needs, extensive scientific, regulatory and IP risks, and additional geopolitical risks tied to its Israeli operations.
Revium Rx is registering up to 1,562,500 Units in a self-underwritten primary offering and up to 37,625,790 shares of common stock for resale by existing stockholders. Each Unit consists of two common shares and one warrant, offered at a fixed price of $3.20 per Unit, with expected net proceeds to the company of about $4.4 million if all Units are sold. Common shares outstanding would rise from 60,729,100 to 63,854,100, excluding shares issuable on new IPO warrants.
The company is a preclinical biotechnology business developing lipid-based drug delivery platforms for antimicrobial resistance, oncology and immunology, built around liposomal and nano-medicine technologies licensed from Hebrew University’s Yissum and acquired via its LipoVation transaction. Revium Rx has a history of losses, expects continued negative cash flow, and will need substantial additional funding beyond this offering.
Key risks include early-stage product candidates with no regulatory approvals, complex and uncertain clinical and regulatory paths, heavy reliance on licensed intellectual property, potential dilution from warrants and resales, penny-stock trading on the OTC market, and operational and geopolitical risks tied to significant R&D activities in Israel and multi-front regional conflict.
Revium Rx (RVRC) filed an amended S-1 registering a self-underwritten primary offering of 1,562,500 Units at a fixed public offering price of $3.20 per Unit (each Unit = two shares + one warrant) and a resale registration for up to 37,625,790 shares by selling stockholders. The Company expects $4,400,000 in net proceeds if all Units sell and no IPO warrants are exercised, and proposes to allocate approximately 55% (~$2.42M) to advance Nano-Mupirocin, 25% (~$1.1M) to Nano-ARB work, and 20% (~$880k) to G&A.
The filing discloses material risks including a history of losses, substantial future funding needs, potential dilution from existing warrants and resale shares, penny-stock trading restrictions, dependence on key officers, IP and regulatory risks for its nanoformulations, and operational exposure from Israeli geopolitical instability. The document also states an existing Non-Clinical Evaluation Agreement with NIAID and exclusive license rights for LPLT vaccine technology, with a SARS-CoV-2 challenge study expected to resume in Q4 2025 and conclude in Q1 2026.